A Post-market Clinical Follow-up Investigation in Healthy Volunteers Measuring Eye Parameters to Verify Performance and Safety of Previct® Drugs for Monitoring of Patients in Treatment of Substance Use Disorder
This is a post-market clinical follow-up study on an approved CE-marked eHealth system where a mobile phone application is used to measure the pupils and eye measurements to monitor the use of different drug substances. The goal of the study is to collect additional information when using the system and to improve the current models for indicating the use of cannabinoids and phenethylamines.
Drug intake of cannabinoid or phenethylamine will in this study be simulated using two commonly used medicines.
The study will include healthy volunteers where each participant will participate in the study for approximately 10 days. The participant will be using the mobile phone application for about a week, first at the clinic and then in the home environment. After approximately a week the participant will visit the clinic to be administered with the selected medicine whereafter the mobile phone application will be used for up to 5 hours. A final phone call will be taken place at approximately day 10, whereafter the participant has completed the study.
A post-market clinical follow-up investigation in healthy volunteers measuring eye parameters to verify performance and safety of Previct® Drugs for monitoring of patients in treatment of substance use disorder - Eye monitoring of substance use disorder
A Second Explorative Pilot Study Evaluating Usability and Functionality of a New Mobile Phone Application Measuring Eye Parameters of Eyes in Patients With Confirmed Substance Use Disorder (SUD)
This will be a pre-market, explorative, early feasibility, pilot, controlled clinical investigation designed to collect initial clinical data for Previct Drugs.
100 Clinical Results associated with Kontigo Care AB
0 Patents (Medical) associated with Kontigo Care AB
100 Deals associated with Kontigo Care AB
100 Translational Medicine associated with Kontigo Care AB